These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 10800651

  • 21. Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors.
    Orentas RJ, Lemas MV, Mullin MJ, Colombani PM, Schwarz K, Ambinder R.
    J Hematother; 1998 Jun; 7(3):257-61. PubMed ID: 9621259
    [Abstract] [Full Text] [Related]

  • 22. Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors.
    Smith C, Khanna R.
    Immunotherapy; 2015 Jun; 7(5):563-72. PubMed ID: 26065480
    [Abstract] [Full Text] [Related]

  • 23. [Adoptive immune therapy using EBV-specific CTL].
    Kuzushima K, Morishima T.
    Nihon Rinsho; 1997 Feb; 55(2):473-8. PubMed ID: 9046843
    [Abstract] [Full Text] [Related]

  • 24. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.
    Bollard CM, Huls MH, Buza E, Weiss H, Torrano V, Gresik MV, Chang J, Gee A, Gottschalk SM, Carrum G, Brenner MK, Rooney CM, Heslop HE.
    Clin Lymphoma Myeloma; 2006 Jan; 6(4):342-7. PubMed ID: 16507214
    [No Abstract] [Full Text] [Related]

  • 25. EBV the prototypical human tumor virus--just how bad is it?
    Thorley-Lawson DA.
    J Allergy Clin Immunol; 2005 Aug; 116(2):251-61; quiz 262. PubMed ID: 16083776
    [Abstract] [Full Text] [Related]

  • 26. Infectious agents in human cancers: lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV.
    Taylor GS, Blackbourn DJ.
    Cancer Lett; 2011 Jun 28; 305(2):263-78. PubMed ID: 21470769
    [Abstract] [Full Text] [Related]

  • 27. Distribution of cell-free and cell-associated Epstein-Barr virus (EBV) DNA in the blood of patients with nasopharyngeal carcinoma and EBV-associated lymphoma.
    Lit LC, Chan KC, Leung SF, Lei KI, Chan LY, Chow KC, Chan AT, Lo YM.
    Clin Chem; 2004 Oct 28; 50(10):1842-5. PubMed ID: 15319320
    [No Abstract] [Full Text] [Related]

  • 28. Epstein-Barr virus-associated cancers: aetiology and treatment.
    Lopes V, Young LS, Murray PG.
    Herpes; 2003 Dec 28; 10(3):78-82. PubMed ID: 14759340
    [Abstract] [Full Text] [Related]

  • 29. Cytotoxic T cells and immunotherapy.
    Kitchingman GR, Rooney C.
    Pediatr Radiol; 1998 Jul 28; 28(7):489-91. PubMed ID: 9662564
    [Abstract] [Full Text] [Related]

  • 30. Current Trends and Alternative Scenarios in EBV Research.
    Minarovits J, Niller HH.
    Methods Mol Biol; 2017 Jul 28; 1532():1-32. PubMed ID: 27873264
    [Abstract] [Full Text] [Related]

  • 31. Epstein-Barr virus-associated lymphoproliferative disorders.
    Rezk SA, Weiss LM.
    Hum Pathol; 2007 Sep 28; 38(9):1293-304. PubMed ID: 17707260
    [Abstract] [Full Text] [Related]

  • 32. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?
    Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, O'Reilly RJ.
    Bone Marrow Transplant; 1995 Apr 28; 15(4):591-4. PubMed ID: 7655386
    [Abstract] [Full Text] [Related]

  • 33. Regulatory T cells and EBV associated malignancies.
    Li J, Qian CN, Zeng YX.
    Int Immunopharmacol; 2009 May 28; 9(5):590-2. PubMed ID: 19539572
    [Abstract] [Full Text] [Related]

  • 34. Post-transplant EBV induced lymphoproliferative disorders.
    Lucas KG, Pollok KE, Emanuel DJ.
    Leuk Lymphoma; 1997 Mar 28; 25(1-2):1-8. PubMed ID: 9130609
    [Abstract] [Full Text] [Related]

  • 35. EBV specific CTL: a model for immune therapy.
    Rooney CM, Heslop HE, Brenner MK.
    Vox Sang; 1998 Mar 28; 74 Suppl 2():497-8. PubMed ID: 9704488
    [Abstract] [Full Text] [Related]

  • 36. Post-transplantation lymphoproliferative disease. Introduction.
    Klein G.
    Springer Semin Immunopathol; 1998 Mar 28; 20(3-4):319-23. PubMed ID: 9870248
    [No Abstract] [Full Text] [Related]

  • 37. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
    Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE, Rooney CM, Bollard CM.
    J Immunol; 2005 Sep 15; 175(6):4137-47. PubMed ID: 16148164
    [Abstract] [Full Text] [Related]

  • 38. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis.
    Tao Q, Swinnen LJ, Yang J, Srivastava G, Robertson KD, Ambinder RF.
    Am J Pathol; 1999 Aug 15; 155(2):619-25. PubMed ID: 10433954
    [Abstract] [Full Text] [Related]

  • 39. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q, Burton R, Reddy V, Lucas KG.
    Br J Haematol; 2002 Sep 15; 118(3):799-808. PubMed ID: 12181048
    [Abstract] [Full Text] [Related]

  • 40. Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
    Heslop HE, Rooney CM.
    Immunol Rev; 1997 Jun 15; 157():217-22. PubMed ID: 9255632
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.